Acute Kidney Injury

  • Paolo Calzavacca
  • Elisa Licari
  • Rinaldo Bellomo


Acute kidney injury (AKI) is the new consensus term for various degrees of acute renal injury or failure.1,2 We will use this term throughout this chapter instead of the previous term “failure” in keeping with such consensus statements. AKI is a frequently diagnosed in patients in the intensive care unit (ICU).3–5 Unfortunately, until recently, the definition of AKI has been a confounding element in its epidemiology.6 This is because the diagnosis of AKI is complex and involves data obtained from history, biochemical analysis, body size, sex, hematological information, and imaging. Accordingly, depending on the definition used,7 the incidence of AKI in ICU is in the range of 1–25%.8–12 In order to develop a widely accepted definition of AKI to facilitate communication and research in this field, the second International Consensus Conference of the Acute Dialysis Quality Initiative in 2002 proposed a classification scheme for AKI.


Intensive Care Unit Glomerular Filtration Rate Renal Replacement Therapy Acute Kidney Injury Intensive Care Unit Patient 


  1. 1.
    Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network (AKIN): report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.PubMedCrossRefGoogle Scholar
  2. 2.
    Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204–R212.PubMedCrossRefGoogle Scholar
  3. 3.
    De Mondança A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 2000;26:915–921.CrossRefGoogle Scholar
  4. 4.
    Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–818.PubMedCrossRefGoogle Scholar
  5. 5.
    Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: physiological principles. Int Care Med. 2004;30:33–37.CrossRefGoogle Scholar
  6. 6.
    Vincent JL. Incidence of acute renal failure in the intensive care unit. Contrib Nephrol. 2001;132:1–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Bellomo R, Kellum JA, Ronco C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Int Care Med. 2007;33(3):409–413.CrossRefGoogle Scholar
  8. 8.
    Weisbord SD, Palevsky PM. Acute renal failure in the intensive care unit. Semin Respir Care Med. 2006;27(3):262–273.CrossRefGoogle Scholar
  9. 9.
    Wiakar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol. 2006;17:1143–1150.CrossRefGoogle Scholar
  10. 10.
    Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10(3):R73.PubMedCrossRefGoogle Scholar
  11. 11.
    Jones DR, Lee HT. Protecting the kidney during critical illness. Curr Opin Anaesth. 2007;20:106–112.CrossRefGoogle Scholar
  12. 12.
    Brivet FG, Kleinknecht DJ, Loirat P, et al. Acute renal failure in intensive care units – Causes, outcomes, and prognostic factors of hospital mortality: a prospective, multicenter study. Crit Care Med. 1996;24(2):192–198.PubMedCrossRefGoogle Scholar
  13. 13.
    Bagshaw SM, George C, Bellomo R, ANZICS Database Management Committee. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care 2007;11(3):R68–R77.Google Scholar
  14. 14.
    Hoste EA, Kellum JA. Incidence, classification, and outcomes of acute kidney injury. Contrib Nephrol. 2007;156:32–38.PubMedCrossRefGoogle Scholar
  15. 15.
    Cruz DN, Ronco C. Acute kidney injury in the intensive care unit: current trends in incidence and outcome. Crit Care. 2007;11(4):R140–R150.CrossRefGoogle Scholar
  16. 16.
    Abosaif NY, Tolba YA, Heap M, et al. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. Am J Kidney Dis. 2005;46(6):1038–1048.PubMedCrossRefGoogle Scholar
  17. 17.
    Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med. 2004;351:159–169.PubMedCrossRefGoogle Scholar
  18. 18.
    Piccini P, Lieta E, Marafon S. Risk factors for acute renal failure in the intensive care unit. Contrib Nephrol. 2001;132:22–35.CrossRefGoogle Scholar
  19. 19.
    Uchino S, Doig GS, Bellomo R, et al. Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T.) investigators. Diuretics and mortality in acute renal failure. Crit Care Med 2004;32(8):1669–1677.Google Scholar
  20. 20.
    Singri N, Ahya SN, Levin ML. Acute renal failure. JAMA. 2003;289(6):747–751.PubMedCrossRefGoogle Scholar
  21. 21.
    Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med. 1996;334(22):1448–1460.PubMedCrossRefGoogle Scholar
  22. 22.
    Ren Y, Garvin J, Carretero OA. Mechanism involved in bradykinin-induced efferent arteriole dilation. Kidney Int. 2002;62(2):544–549.PubMedCrossRefGoogle Scholar
  23. 23.
    Kramer HJ, Horacek V, Bäcker A, et al. Relative roles of nitric oxide, prostanoids and angiotensin II in the regulation of canine glomerular hemodynamics. A micropuncture study. Kidney Blood Press Res. 2004;27(1):10–17.PubMedCrossRefGoogle Scholar
  24. 24.
    Langenberg C, Bellomo R, May C, et al. Renal blood flow in sepsis. Crit Care. 2005;9:R363–R374.PubMedCrossRefGoogle Scholar
  25. 25.
    Kellum JA. Prerenal azotemia: still a useful concept? Crit Care Med. 2007;35(6):1630–1631.PubMedCrossRefGoogle Scholar
  26. 26.
    Bellomo R, Bagshaw SM, Langenberg C, et al. Pre-renal azotemia: a flawed paradigm in critically ill septic patients? Contrib Nephrol. 2007;156:1–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Taber SS, Mueller BA. Drug-associated renal dysfunction. Crit Care Clin. 2006;22(2):357–374.PubMedCrossRefGoogle Scholar
  28. 28.
    Sheridan AM, Bonventre JV. Pathophysiology of ischemic acute renal failure. Contrib Nephrol. 2001;132:7–21.PubMedCrossRefGoogle Scholar
  29. 29.
    Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med. 2002;137:744–752.PubMedCrossRefGoogle Scholar
  30. 30.
    Evenepoel P. Acute toxic renal failure. Best Pract Res Clin Anaest. 2004;18(1):37–52.CrossRefGoogle Scholar
  31. 31.
    Langenberg C, Bellomo R, et al. Renal blood flow in experimental septic acute renal failure. Kidney Int. 2006;69:1996–2002.PubMedCrossRefGoogle Scholar
  32. 32.
    Bywaters EGL, Beall D. Crush injuries with impairment of renal function. BMJ. 1941;1:427–432.PubMedCrossRefGoogle Scholar
  33. 33.
    Teschan PE, Post RS, Sith LH, et al. Post-traumatic renal insufficiency in military casualties. I. Clinical characteristics. Am J Med. 1955;18:172–186.PubMedCrossRefGoogle Scholar
  34. 34.
    Miller TR, Anderson RJ, Schrier RW, et al. Urinary diagnostic indices in acute renal failure: a prospective study. Ann Int Med. 1978;89:47–50.PubMedCrossRefGoogle Scholar
  35. 35.
    Bagshaw SM, Langenberg C, Bellomo R. Urinary biochemistry and microscopy in septic acute renal failure: a systematic review. Am J Kidney Dis. 2006;48(5):695–705.PubMedCrossRefGoogle Scholar
  36. 36.
    Bagshaw SM, Langenberg C, Wan L, et al. A systematic review of urinary findings in experimental septic acute renal failure. Crit Care Med. 2007;35(6):1592–1598.PubMedCrossRefGoogle Scholar
  37. 37.
    Katoli RE, Woods WT, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32:64–71.CrossRefGoogle Scholar
  38. 38.
    Kellum JA, Leblanc M, Gibney RTN, et al. Primary prevention of acute renal failure in the critically ill. Curr Opin Crit Care. 2005;11:537–541.PubMedGoogle Scholar
  39. 39.
    Marenzi G, Bartorelli AL. Recent advances in the prevention of radiocontrast-induced nephropathy. Curr Opin Crit Care. 2004;10:505–509.PubMedGoogle Scholar
  40. 40.
    Briguori C, Airoldi F, Morici N, Colombo A. New pharmacological protocols to prevent or reduce contrast media nephropathy. Minerva Cardioangiol. 2005;53:49–58.PubMedGoogle Scholar
  41. 41.
    Lin J, Bonventre JV. Prevention of radiocontrast nephropathy. Curr Opin Nephrol Hypertens. 2005;14:105–110.PubMedCrossRefGoogle Scholar
  42. 42.
    Mueller C, Buerkle G, Buettner HJ. Prevention of contrast media-associated nephropathy: randomised comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Int Med. 2002;162:329–336.CrossRefGoogle Scholar
  43. 43.
    Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate. A randomised controlled trial. JAMA. 2004;291(19):2328–2334.PubMedCrossRefGoogle Scholar
  44. 44.
    Rudnick MR, Goldfarb S, Wexler L, et al. The Iohexol Cooperative Study. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995;47:254–261.Google Scholar
  45. 45.
    Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–184.PubMedCrossRefGoogle Scholar
  46. 46.
    Baker CSR, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Card. 2003;41:2114–2118.CrossRefGoogle Scholar
  47. 47.
    Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598–603.PubMedCrossRefGoogle Scholar
  48. 48.
    Kshirsagar AV, Poole C, Mottl A, et al. N-Acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004;15:761–769.PubMedCrossRefGoogle Scholar
  49. 49.
    Hoffmann U, Fischereder M, Krüger B, et al. The value of N-Acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407–410.PubMedCrossRefGoogle Scholar
  50. 50.
    Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy. Arch Int Med. 2005;165:1087–1093.CrossRefGoogle Scholar
  51. 51.
    Stone GW, McCullough PA, Tumlin JA, et al. CONTRAST Investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy. A randomised controlled trial. JAMA 2003;290(17):2284–2291.Google Scholar
  52. 52.
    Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416–1420.PubMedCrossRefGoogle Scholar
  53. 53.
    Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333–1340.PubMedCrossRefGoogle Scholar
  54. 54.
    Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409.PubMedCrossRefGoogle Scholar
  55. 55.
    Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 1998;27:35–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Arroyo V, Terra C, Gines P. New treatment of hepatorenal syndrome. Semin Liver Dis. 2006;26(3):254–264.PubMedCrossRefGoogle Scholar
  57. 57.
    Cole L, Bellomo R, Silvester W, et al. A prospective, multicenter study of the epidemiology, management and outcome of severe acute renal failure in a “closed” ICU system. Am J Respir Crit Care Med. 2000;162:191–196.PubMedCrossRefGoogle Scholar
  58. 58.
    Needham E. Management of acute renal failure. Am Fam Physician. 2005;72:1739–1746.PubMedGoogle Scholar
  59. 59.
    Bellomo R. How to feed patients with renal dysfunction. Blood Purif. 2002;20:296–303.PubMedCrossRefGoogle Scholar
  60. 60.
    Macias J, Alaka KJ, Murphy MH, et al. Impact of the nutritional regimen on protein catabolism and nitrogen balance in patients with renal failure. JPEN J Parenter Enteral Nutr. 1996;20:56–62.PubMedCrossRefGoogle Scholar
  61. 61.
    Leverve XM, Cano NJ. Nutritional management in acute illness and acute kidney insufficiency. Contrib Nephrol. 2007;156:112–118.PubMedCrossRefGoogle Scholar
  62. 62.
    Cano N, Fiaccadori E, et al. ESPEN (European Society for Parenteral and Enteral Nutrition) Guidelines on Enteral Nutrition: adult renal failure. Clin Nutr. 2006;25(2):295–310.PubMedCrossRefGoogle Scholar
  63. 63.
    Marshall MR, Golper TA, Shaver MJ, et al. Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. Am J Kidney Dis. 2002;39:556–570.PubMedCrossRefGoogle Scholar
  64. 64.
    Freire AX, Bridges L, Umpierrez GE, et al. Admission hyperglycemia and other risk factors as predictors of hospital mortality in a medical ICU population. Chest. 2005;128(5):3109–3116.PubMedCrossRefGoogle Scholar
  65. 65.
    Story D, Ronco C, Bellomo R. A prospective, controlled study of trace element and vitamin concentrations and losses n critically ill patients treated with continuous veno-venous hemofiltration. Crit Care Med. 1999;27:220–223.PubMedCrossRefGoogle Scholar
  66. 66.
    Chioléro R, Berger MM. Nutritional support during renal replacement therapy. Contrib Nephrol. 2007;156:267–274.PubMedCrossRefGoogle Scholar
  67. 67.
    Liangos O, Pereira BJG, Jaber BL. Anemia in acute renal failure: role for erythropoiesis-stimulating proteins? Artif Organs. 2003;27(9):786–791.PubMedCrossRefGoogle Scholar
  68. 68.
    Gettings LG, Reynolds HN, Scalea T. Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs. late. Intensive Care Med. 1999;25:805–813.PubMedCrossRefGoogle Scholar
  69. 69.
    Bellomo R, Goldsmith D, Uchino S, et al. Prospective controlled trial of effect of medical emergency team on postoperative morbidity and mortality rates. Crit Care Med. 2004;32:916–921.PubMedCrossRefGoogle Scholar
  70. 70.
    Bagshaw SM, Bellomo R. Fluid resuscitation and the septic kidney. Curr Opin Crit Care. 2006;12(6):527–530.PubMedCrossRefGoogle Scholar
  71. 71.
    Licari E, Calzavacca P, Ronco C, et al. Fluid resuscitation and the septic kidney: the evidence. Contrib Nephrol. 2007;156:167–177.PubMedCrossRefGoogle Scholar
  72. 72.
    Wiedemann HP, Wheeler AP, Bernard GR. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564–2575.PubMedCrossRefGoogle Scholar
  73. 73.
    Finfer F, Bellomo R, Boyce N. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256.PubMedCrossRefGoogle Scholar
  74. 74.
    Bellomo R, Kellum JA, Wisniewski SR, et al. Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med. 1999;159:1186–1192.PubMedCrossRefGoogle Scholar
  75. 75.
    Redl-Wenzel EM, Armbruster C, Edelman G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock. Intensive Care Med. 1993;19:151–154.CrossRefGoogle Scholar
  76. 76.
    Bersten AD, Holt AW. Vasoactive drugs and the importance of renal perfusion pressure. New Horizons. 1995;3:650–661.PubMedGoogle Scholar
  77. 77.
    McDonald RH, McNay JL, Goldberg LI, et al. Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate and renal plasma flow. J Clin Invest. 1964;43:1116–1124.PubMedCrossRefGoogle Scholar
  78. 78.
    McNay JL, McDonald RH, Goldberg LI. Direct renal vasodilation produced by dopamine in dog. Circ Res. 1965;16:510–517.PubMedCrossRefGoogle Scholar
  79. 79.
    D’Orio V, El Allaf D, Juchmes J, et al. The use of low-dose dopamine in intensive care medicine. Arch Int Physiol Biochim Biophys. 1984;92(Suppl):S11–S20.CrossRefGoogle Scholar
  80. 80.
    Hoogenberg K, Smit AJ, Girbers ARJ. Effects of low-dose dopamine on renal and systemic hemodynamics during incremental norepinephrine infusion in healthy volunteers. Crit Care Med. 1998;26:260–265.PubMedCrossRefGoogle Scholar
  81. 81.
    Thompson BT, Cockrill BA. Renal-dose dopamine: a siren song? Lancet. 1994;344:7–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Cuthberston BH, Noble DW. Dopamine in oliguria. Should be used for specific conditions, not as a prophylaxis. BMJ. 1997;314:690–691.CrossRefGoogle Scholar
  83. 83.
    Debayeve YA, Van den Berge G. Is there still a place for dopamine in the modern intensive care unit? Anesth Analg. 2004;98:461–468.CrossRefGoogle Scholar
  84. 84.
    Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29(8):1526–1531.PubMedCrossRefGoogle Scholar
  85. 85.
    Marik PE. Low dose dopamine: a systemic review. Int Care Med. 2002;28:877–883.CrossRefGoogle Scholar
  86. 86.
    Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142:510–524.PubMedCrossRefGoogle Scholar
  87. 87.
    Zacharias M, Gilmore ICS, Herbison GP, et al. Interventions for protecting renal function in the perioperative period. Cochrane Database Syst Rev 2005;(3):CD003590.Google Scholar
  88. 88.
    Kellum JA. The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence. Crit Care Med. 1997;1:53–59.CrossRefGoogle Scholar
  89. 89.
    Holmes CL, Walley KR. Bed medicine: low dose dopamine in the ICU. Chest. 2003;123:1266–1275.PubMedCrossRefGoogle Scholar
  90. 90.
    Jones D, Bellomo R. Renal-dose dopamine: from hypothesis to paradigm to dogma to myth and, finally, superstition? J Intensive Care Med. 2005;20:199–211.PubMedCrossRefGoogle Scholar
  91. 91.
    The Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. A multicenter, randomised, double-blind, placebo-controlled trial of low dose dopamine in patients with early renal dysfunction. Lancet 2000;356:2139–2143.Google Scholar
  92. 92.
    Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit Care Med. 1994;22:1919–1925.PubMedGoogle Scholar
  93. 93.
    Denton MD, Chertow GM, Brady HR. “Renal-dose” dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int. 1996;49:4–14.CrossRefGoogle Scholar
  94. 94.
    Dehan A, Ward D, van den Elsen M, et al. Influence of reduced carotid body drive during sustained hypoxia or hypoxic depression of ventilation in humans. J Appl Physiol. 1996;81:565–572.Google Scholar
  95. 95.
    Nevière R, Mathieu D, Chagnon JL, et al. The contrasting effects of dobutamine and dopamine on gastric mucosal perfusion in septic patients. Am J Respir Crit Care Med. 1996;154:1684–1688.PubMedCrossRefGoogle Scholar
  96. 96.
    Dive A, Foret F, Jamart J, et al. Effects of dopamine on gastrointestinal motility during critical illness. Int Care Med. 2000;26:901–907.CrossRefGoogle Scholar
  97. 97.
    Bernton EW, Meltzer MS, Holaday JW. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science. 1988;239:401–404.PubMedCrossRefGoogle Scholar
  98. 98.
    Devins SS, Miller A, Herndon BL, et al. Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. Crit Care Med. 1992;20:1644–1649.PubMedCrossRefGoogle Scholar
  99. 99.
    Van den Berge G, de Zegher F, Lauwers P. Dopamine suppresses pituitary function in infants and children. Crit Care Med. 1994;22:1747–1753.Google Scholar
  100. 100.
    Van den Berge G, de Zegher F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol. 1994;41:731–737.CrossRefGoogle Scholar
  101. 101.
    Juste RN, Moran L, Hooper J, et al. Dopamine clearance in critically ill patients. Int Care Med. 1998;24:1217–1220.CrossRefGoogle Scholar
  102. 102.
    Allison NL, Dubb JW, Ziemniak JA, et al. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther. 1987;41:282–288.PubMedCrossRefGoogle Scholar
  103. 103.
    Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis. 1998;31:743–755.PubMedCrossRefGoogle Scholar
  104. 104.
    Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med. 1999;27:1832–1837.PubMedCrossRefGoogle Scholar
  105. 105.
    Halpenny M, Lakshmi S, O’Donnell A, et al. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia. 2001;56(10):953–960.PubMedCrossRefGoogle Scholar
  106. 106.
    Halpenny M, Rushe C, Breen P, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol. 2002;19(1):32–39.PubMedGoogle Scholar
  107. 107.
    Bove T, Landoni G, Calabrò MG, et al. Renoprotective action of fenoldopam in high risk patients undergoing cardiac surgery. Circulation. 2005;111:3230–3235.PubMedCrossRefGoogle Scholar
  108. 108.
    Caimmi PP, Pagani L, Micalizzi E, et al. Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003;17(4):491–494.PubMedCrossRefGoogle Scholar
  109. 109.
    Russo D, Memoli B, Andreucci VE. The place of loop diuretics in the treatment of acute and chronic renal failure. Clin Nephrol. 1992;38(Suppl 1):S69–S73.PubMedGoogle Scholar
  110. 110.
    Swärd K, Valsson F, Sellgren J, et al. Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate and renal oxygen consumption in human. Int Care Med. 2005;31(1):79–85.CrossRefGoogle Scholar
  111. 111.
    Mehta RL, Pascual MT, Soroko S, et al. PICARD Study Group. Diuretics, mortality and nonrecovery of renal function in acute renal failure. JAMA 2002;288(20):2547–2553.Google Scholar
  112. 112.
    Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ. 2006;333:420–426.PubMedCrossRefGoogle Scholar
  113. 113.
    Bagshaw S, Delaney A, Haase M, et al. Loop diuretics in the management of acute renal failure: a systemic review and meta-analysis. Crit Care Resusc. 2007;9(1):60–68.PubMedGoogle Scholar
  114. 114.
    Girbes AR. Prevention of acute renal failure: role of vaso-active drugs, mannitol and diuretics. Int J Artif Organs. 2004;27(12):1049–1053.PubMedGoogle Scholar
  115. 115.
    Ali F, Guglin M, Vaitkevicius P, et al. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847–858.PubMedCrossRefGoogle Scholar
  116. 116.
    Holmes CL, Walley KR. Vasopressin in the ICU. Curr Opin Crit Care. 2004;10(6):442–448.PubMedCrossRefGoogle Scholar
  117. 117.
    Bellomo R, Ronco C. Indications and criteria for initiating renal replacement therapy in the intensive care unit. Kidney Int. 1998;53(Suppl 66):S106–S109.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Paolo Calzavacca
    • 1
  • Elisa Licari
    • 1
  • Rinaldo Bellomo
    • 1
  1. 1.Department of Intensive CareAustin HospitalVictoriaAustralia

Personalised recommendations